SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Jonathan Weiss/Shutterstock
Business
Takeda Spins Out HilleVax to Propel Final Development of Norovirus Vaccine
Collaborating with Frazier Healthcare Partners, the team spun out a new company dubbed HilleVax to take Takeda’s norovirus vaccine into Phase 3 trials.
July 30, 2021
 · 
2 min read
 · 
Kate Goodwin
Biotech Beach
Ring Hopes to Bring First Re-dosable Gene Therapy to the Clinic with $117M Series B
Ring Therapeutics hopes to bring in a “new era of gene therapies” to rise above the challenges of current options. A cohort of investors bought into the hope with a $117 million Series B funding round.
July 28, 2021
 · 
2 min read
 · 
Kate Goodwin
Job Trends
Deep Genomics is Rewriting RNA for Powerful Therapeutics with $180M Series C
“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
July 28, 2021
 · 
3 min read
 · 
Kate Goodwin
Biotech Bay
Money on the Move: July 21 – 27, 2021
A quick overview of life science companies scooping up some summer spending money this week.
July 28, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Artios Adds $153M to the Bank Amidst a Year of Major Collab Deals
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
July 27, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
PerkinElmer Continues Rapid Life Science Growth with Massive $5.25B Acquisition
It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
July 26, 2021
 · 
2 min read
 · 
Kate Goodwin
Nathan Stirk/Getty Images
FDA
Wins for AstraZeneca: Diabetes Drug Approved for Teens, Covid Vaccine Effective against Delta Variant
The FDA has now approved AstraZeneca’s convenient once-a-week glucose lowering drug for 10 to 17-year-olds with type 2 diabetes.
July 23, 2021
 · 
2 min read
 · 
Kate Goodwin
Erik McGregor/LightRocket via Getty
Business
Pfizer Strengthens Cancer Standing with Protein Degrader Collaboration
This week the pharma giant announced a second collaboration agreement with Connecticut-based Arvinas to develop and commercialize its PROTAC estrogen receptor protein degrader.
July 22, 2021
 · 
2 min read
 · 
Kate Goodwin
Pictured: J&J sign and office in Ontario/i
Pharm Country
J&J Highlight Massive Q2 Earnings While Covid Vaccine Doubts Grow and Legal Battles Rage
As Johnson & Johnson touted $23.3 billion sales on its Q2 earnings call this morning, other news in the media hasn’t been as kind to the massive, global conglomerate.
July 21, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: July 14 – 21
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
July 21, 2021
 · 
5 min read
 · 
Kate Goodwin
Genetown
Amylyx Scores $135 Million for ALS Drug with Hopes for Quick Approval
The Boston-based company announced an infusion of $135 million in Series C funds to support the late-stage development of its lead candidate, AMX0035, for amyotrophic lateral sclerosis.
July 20, 2021
 · 
3 min read
 · 
Kate Goodwin
FDA
Kadmon’s Chronic GVHD Drug Wins First FDA Approval for Company
On Friday, the agency approved belumosudil as a new treatment option for anyone over 12 with cGVHD after two prior lines of therapy have failed.
July 19, 2021
 · 
2 min read
 · 
Kate Goodwin
Smith Collection/Gado/Getty Images
Policy
Pfizer Offers $345 Million to Settle Out of EpiPen Pricing Lawsuit
In 2016, Mylan’s EpiPen became the flashpoint of drug pricing outrage when it became widely reported the life-saving drug had increased more than 400% in price over a period of seven years.
July 16, 2021
 · 
3 min read
 · 
Kate Goodwin
NBTXR3 helping in strengthening immune system.
With $172 Million Raise, Wugen Brings Natural Killer Therapies to Solid Tumors Next
Its lead product, WU-NK-101, is already proving itself in an ongoing Phase I/II trial, demonstrating an “impressive complete response rate in relapsed/refractory AML.”
July 15, 2021
 · 
2 min read
 · 
Kate Goodwin
President Joe Biden/VP Brothers, Shutterstock
Policy
Pharma Faces a Turn in the Tides as Biden Demands Health Care Reforms
Biden calls out the Health and Human Services department to submit a plan in the next 45 days to combat excessive drug prices and enhance domestic pharmaceutical supply chains.
July 14, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More